title: Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
abstract: Hyperglycaemia, a raised fibrinogen, an increased serum triglyceride and a reduced HDL-cholesterol are common metabolic features of non-insulin dependent diabetes mellitus (NIDDM). Hypertension is frequently associated with NIDDM, however the influence of antihypertensive therapy on these combined factors in the diabetic is at present unclear. In a double-blind placebo-controlled crossover study in 20 stable NIDDM subjects with hypertension, the metabolic effects of 6 weeks' treatment with the alpha-blocker, doxazosin, was compared with treatment with the beta-blocker, atenolol. Similar and significant reductions in BP were produced by both drugs. Significant increases in weight, HbA1, apoprotein B, serum triglyceride and cholesterol/HDL ratio were observed with atenolol therapy. Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant. Fibrinogen was not altered by either treatment. Conclusions from this study indicate; 1) adrenergic mechanisms may be an important influence on glucose homeostasis and lipid metabolism in NIDDM and 2) the beta-blocker, atenolol, has a small adverse effect on weight, glycaemic control and the atherogenic lipid profile, whereas the alpha-blocker, doxazosin, has no such effect and may, in part, correct the disturbances of lipoprotein metabolism characteristic of NIDDM.
authors.affiliation: Department of Clinical Pharmacology, St. Mary's Hospital Medical School, London, UK.
authors.forename: M D
authors.initials: MD
authors.lastname: Feher
authors.forename: A D
authors.initials: AD
authors.lastname: Henderson
authors.forename: J
authors.initials: J
authors.lastname: Wadsworth
authors.forename: C
authors.initials: C
authors.lastname: Poulter
authors.forename: S
authors.initials: S
authors.lastname: Gelding
authors.forename: W
authors.initials: W
authors.lastname: Richmond
authors.forename: P S
authors.initials: PS
authors.lastname: Sever
authors.forename: R S
authors.initials: RS
authors.lastname: Elkeles
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D001262:Atenolol / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000378:metabolism; D004311:Double-Blind Method; D017292:Doxazosin; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D008074:Lipoproteins; D001262:Atenolol; D005947:Glucose; D017292:Doxazosin; D011224:Prazosin